<DOC>
	<DOCNO>NCT02496741</DOCNO>
	<brief_summary>This phase Ib , open-label , single-center , non-randomized clinical trial evaluate toxicity efficacy metformin chloroquine isocitrate dehydrogenase 1/2-mutated ( IDH1/2MT ) patient glioma , intrahepatic cholangiocarcinoma chondrosarcoma .</brief_summary>
	<brief_title>Metformin And Chloroquine IDH1/2-mutated Solid Tumors</brief_title>
	<detailed_description>Glioma , intrahepatic cholangiocarcinoma ( IHCC ) chondrosarcoma ( CS ) aggressive , malignant cancer dismal outcome , two latter type especially locally-advanced metastasized setting . This due lack effective treatment strategy highlight dire need novel therapy . A subset cancer type characterize presence mutation gene encode isocitrate dehydrogenase 1 ( IDH1 ) isocitrate dehydrogenase 2 ( IDH2 ) . These mutation occur 80 % world health organization ( WHO ) grade II III glioma secondary glioblastoma , 20 % IHCC 60 % CS , besides oncogenic function , induce metabolic vulnerability IDH1/2MT cancer cell exploit vitro oral antidiabetic metformin oral antimalarial drug chloroquine . In present study protocol , investigator describe phase Ib single-center clinical trial patient glioma , IHCC CS screen IDH1/2MT use surrogate marker D-2-hydroxyglutarate ( D-2HG ) , exclusively produce IDH1/2MT cancer , DNA sequence tumor material . Eligible IDH1/2MT patient treat combination metformin chloroquine . The study protocol use 3+3 dose-escalation scheme . The primary objective determine maximum tolerate dose order establish recommend dose phase II trial . Secondary objective study include ( 1 ) investigate pharmacokinetics combination therapy metformin plus chloroquine , ( 2 ) whether IDH1/2MT status determine magnetic resonance spectroscopy and/or mass spectrometry serum , urine and/or bile next-generation sequence circulate tumor DNA glioma , IHCC CS patient ( 3 ) investigate tumor response D-2HG concentration response metformin plus chloroquine IDH1/2MT cancer . This study may open novel treatment avenue IDH1/2MT glioma , IHCC CS investigate two relatively safe drug highly malignant tumor . In addition , study may present novel therapy cancer regularly affect IDH1/2MT , acute myeloid leukemia , acute lymphocytic leukemia T-cell lymphoma .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Chondrosarcoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>1 . Presence glioma , IHCC WHO grade ≥ II CS ( newlydiagnosed refractory/relapsed tumor ) 2 . Tumor carry neomorphic D2HG generate mutation IDH1 IDH2 determine MS serum urine ( optional : bile ) , MRS tumor DNA sequencing ( circulate ) tumor material . 3 . Measurable lesion accord RECIST 1.1 criterion ( see Appendix B ) IHCC CS patient RANO criterion ( see Appendix C ) glioma patient . 4 . ECOG/WHO performance 02 ( see Appendix D ) . 5 . Age &gt; 18 year . 6 . Adequate renal function ( creatinine &lt; 150 μmol/L and/ creatinine clearance &gt; 60 ml/ L ) . 7 . Adequate liver function ( bilirubin &lt; 1.5 time upper limit normal , ALAT ASAT &lt; 5.0 time upper limit normal case liver metastases &lt; 2.5 upper limit normal absence liver metastasis ) . 8 . Adequate bone marrow function ( WBC &gt; 3.0 x 109/L , platelet &gt; 100 x 109/L ) . 9 . If patient eligible resection , surgery ( already ) plan least 4 week away start study treatment . 10 . Mentally , physically , geographically able undergo treatment follow . 11 . Signed informed content obtain prior treatment . 1 . Pregnancy ( positive serum pregnancy test ) lactation . 2 . Serious concomitant systemic disorder would compromise safety patient , discretion investigator . 3 . Patients severe and/or uncontrolled medical condition : unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction , cardiac arrhythmia , pulmonary insufficiency , epilepsy ( interaction chloroquine ) , severe gastrointestinal , neurological hematological disease ( interaction chloroquine ) . 4 . 6 month prior randomization : serious uncontrolled cardiac arrhythmia , uncontrolled diabetes define fast serum glucose &gt; 2X ULN , active uncontrolled severe infection , include malaria , cirrhosis , chronic active hepatitis chronic persistent hepatitis , severely impaired lung function . 5 . Patients use digoxin , MAO inhibitor , fenylbutazone , oxygenbutazone , gold preparation cimetidine ( know pharmaco interaction chloroquine ) loop diuretic ( know pharmaco interaction metformin ) good alternative available . 6 . Patients known history alcohol abuse ( interaction metformin ) . 7 . Patients know glucose6phosphate dehydrogenase deficiency , porphyria , myasthenia gravis ocular/retinal aberration ( interaction chloroquine ) . 8 . Patients know hypersensitivity metformin chloroquine . 9 . Patients lactose intolerant . 10 . Use metformin chloroquine previous 6 month . 11 . Longterm use chloroquine ( &gt; 5 year cumulative dose &gt; 300 gram ) past . 12 . Use anticancer therapy ( i.e . surgical resection , chemotherapy , target therapy , radiation therapy , surgery ) . Palliative therapy permit , : palliative radiotherapy symptomatic bone metastasis ; dexamethasone symptom relief patient glioma cerebral edema ; nonenzyme induce antiepileptic drug ( exception topiramate ) patient glioma epileptic seizure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>isocitrate dehydrogenase 1/2 mutation</keyword>
	<keyword>metformin</keyword>
	<keyword>chloroquine</keyword>
</DOC>